Table 1.

SCALE Obesity and Prediabetes: endpoints at week 160 [a] n = 886 (early responders), n = 416 (early non-responders): [b] Increase in score indicates improvement.

Week 0–160	Early responders to liraglutide 3.0 mg n=580
Change in body weight (%)	–8.6
Change in body weight (kg)	–9.1
Proportion achieving ≥5% weight loss (%)	65.4
Proportion achieving >10% weight loss (%)	36.7
Proportion achieving >15% weight loss (%)	19.0
Proportion developing T2D (%) [a]	0.5
Proportion regressing to normoglycaemia (%) [a]	69.8
Change in FPG (mg/dL)	–7.75
Change in FPG (mmol/L)	–0.43
Change in HbA1c (%)	–0.44
Change in SBP (mmHg)	–3.74
Change in SF-36 physical component summary score [b]	+3.68
Change in IWQoL-Lite total score [b]	+13.40